Health Friday 11.20.2026 Open Thread: The COVID-19 Bioweapon “Vaccines” and Dementia: Part Three, Section B: the N1-methylpseudouridine Formulation Patent by Weissman – Kariko

The image of N1-methylpseudouridine for today’s offering header is courtesy of Wikipedia and Google Images.

Health Friday is a series devoted to information about Big Pharma, vaccines, general health, and associated topics. There are Important Notifications from our host, Wolf Moon; the Rules of our late, good Wheatie; and, certain caveats from Yours Truly, of which readers should be aware. They are linked here. Note: AI-generated items in today’s offering will be cited as such. If readers wish to post AI-generated items to today’s discussion thread, they must cite their source. Thank you.

This mini-series is dedicated to the memory of Yours Truly’s brother, Samuel R. Lewis, Jr. (24 November 1948 – 29 October 2024.) May he rest in eternal Peace. Love you, Sam. Miss you.

Part One of this mini-series is here: https://www.theqtree.com/2026/10/30/health-friday-10-30-2026-open-thread-the-covid-19-bioweapon-vaccines-and-dementia-part-one/. Part Two is here: https://www.theqtree.com/2026/11/06/health-friday-11-6-2026-open-thread-the-covid-19-vaccines-and-dementia-part-two/. Part Three, Section A, is here: https://www.theqtree.com/2026/11/13/health-friday-11-13-2026-open-thread-the-covid-19-bioweapon-vaccines-and-dementia-part-three-section-a/. Note: None of the content of any post of this mini-series is to be construed as a “hit piece” on either Dr. Weissman or Dr. Kariko.

>>>>>>>>>>>>>>>>>>>>

The COVID-19 Bioweapon “Vaccines” and Dementia: Part Three, Section B: the N1-methylpseudouridine Formulation Patent by Weissman – Kariko

This is US11060107B2, the Patent for the invention of an N1-methylpseudouridine formulation by Dr. Drew Weissman, MD, and Dr. Katalin Kariko, PhD, in 2017, at the University of Pennsylvania (https://patents.google.com/patent/US11060107B2/en.) This is the N1-methylpseudouridine formulation that was used in the Pfizer-BioNTech original COVID-19 bioweapon “vaccine” BNT162b2 (subsequently approved by the FDA under the brand name COMIRNATY on 23 August 2021); and, from there, is currently used in all COMIRNATY “descendant SARS-CoV-2 variant booster vaccines”, also approved by the FDA. This is also the N1-methylpseudouridine formulation that was used in the Moderna original COVID-19 bioweapon “vaccine”, mRNA-1273 (subsequently approved by the FDA under the brand name SPIKEVAX on 31 January 2022), and is currently used in all SPIKEVAX “descendant SARS-CoV-2 variant booster vaccines” made by this company and approved by the FDA; and, in the company’s later, “lite” version of said “vaccine”, mRNA-1283 (subsequently approved by the FDA under the brand name mNEXPIKE on 30 May 2025.)

The following is not to overwhelm the reader with exhibits from the above Patent. The reader will see with their own eyes that the exhibits illustrate some of the depth and breadth of the cold, disciplined, focused attainment of a certain end product by the Patent’s inventors. This end product was the invention of one chemical compound — the N1-methylpseudouridine formulation in the above Patent — that would accomplish six goals, those goals being:

One: to destroy any or all of the four building blocks of RNA in the human body (Uridine [Uracil]; Adenine; Guanine; and, Cytosine — with Uridine being the first choice);

Two: to make sure that the RNA building block(s) are destroyed completely (100% elimination) — thus, silencing the body’s natural ability to recognize an “enemy invader” and signal the immune system to eliminate said “enemy invader”;

Three: to replace the destroyed RNA building block(s) with a lab-created sequence which mimics the destroyed sequences — thus allowing other types of “enemy invaders” to have free access to every cell in the body;

Four: to function as a “carrier” for elements into every cell of the body which “instruct” the cells to make copies of “a protein of interest” (for example, the spike protein of SARS-CoV-2);

Five: to have this invention utilized as a gene therapy treatment for various conditions that impact humans (“cancer”; “cystic fibrosis”; and, “infectious diseases” [for example, COVID-19] are among the conditions listed in the Patent); and,

Six: to have this invention encapsulated (wrapped) into a lipid nanoparticle (or lipid nanoparticles) and/or into a liposome (or into liposomes), so that this invention can also carry instructions to the cells of the body to produce (or to reproduce) a “protein of interest.” The “protein of interest” is also encapsulated (wrapped) into the same lipid nanoparticle(s) and/or liposome(s).

The N1-methylpseudouridine formulation in US11060107B2 satisfied the six goals.

**** Be aware that this N1-methylpseudouridine formulation invention by Dr. Weissman and Dr. Kariko was funded by taxpayer money via the NIH. This would STRONGLY imply that Dr. Francis Collins AND/OR Dr. Anthony Fauci knew about the funding, and about the experiments that the funding paid for.

The subsequent use of this N1-methylpseudouridine formulation invention by Dr. Weissman and Dr. Kariko in BNT162b2 / COMIRNATY (and, by the way, ALSO in Moderna’s mRNA-1273 / SPIKEVAX and mRNA-1283 / mNEXSPIKE COVID-19 bioweapon “vaccines”) is also confirmed: see below in today’s offering.

The lipid nanoparticles used by Pfizer-BioNTech to encapsulate the N1-methylpseudouridine + spike protein (“protein of interest”) payloads are: for BNT162b2 / COMIRNATY: ALC-0159 and ALC-0315 (these, in and of themselves, are dangerous compounds that are for research purposes only.) The lipid nanoparticle used by Moderna to encapsulate the N1-methylpseudouridine + spike protein (“protein of interest”) payloads for SPIKEVAX and mNEXSPIKE is: SM-102 (this, in and of itself, is a dangerous compound that is for research purposes only.) Both companies also use other lipid nanoparticles (for example, PEG2000-DMG), to assist in the payload carriage.

>>>>>>>>>>>>>>>>>>>>

It is crucial to understand that the Uridine RNA of the body — the same Uridine that performs multiple beneficial functions and/or regulates multiple mechanisms of the body, including signalling the immune system to the presence of an “enemy invader” and assisting in learning, memory, and mood control — is 100% destroyed by the N1-methylpseudouridine as formulated in this Patent, and which formulation is used in all COVID-19 bioweapon “vaccines” manufactured by Pfizer-BioNTech and by Moderna. The destruction of the Uridine RNA is accomplished by several processes, including: high-pressure chromatography; heating; and, enzymatic “digestion” via: RNase III; RNaseV1 (COBRA VENOM); “Dicer” (which breaks dsRNA [double-stranded RNA] into tiny bits), and “Chipper” (a lab-use version of a COMMERCIALLY AVAILABLE ENZYME-BASED CLEANING PRODUCT.) The Patent allows for these processes to be used alone, or in combination. The reader will also see that, for example, Uridine (one of the building blocks of RNA for human life) is considered to be an item to be “purified” (destroyed) of “contaminants” (the double-stranded RNA that is essential for Uridine.)

Please see the exhibits from the Patent, below, beginning with the Title and Date Summary, followed by the seven Claims, then the Statement of Funding:

From the Summary of the Invention:

From the Brief Description of the Drawings section, Figure 3A and Figure 3B. These are images of how the RNA signalling elements are destroyed (termed “eliminates immunogenicity” in the text) by N1-methylpseudouridine via a high-pressure chromatography process called HPLC purification:

From the Detailed Description of the Invention section, the following exhibits: **** The following are where the goals of Uridine destruction, replacement with the “fake Uridine sequence”, and to carry an mRNA which instructs the body produce a “protein of interest” are described. The actual Detailed Description of the Invention section is quite long. Please see the portions from this section, below:

The next exhibit describes the use of the N1-methylpseudouridine formulation in the Patent in the ORF (Open Reading Frame) of the SARS-CoV-2 virus code structure:

The following exhibits speak to the “regulation” of the mechanism of the N1-methylpseudouridine formulation in the Patent: in other words, that the time frame of the formulation’s actions can be altered:

>>>>>>>>>>>>>>>>>>>>

What follows are citations and references regarding items listed in the above Patent:

For m5C (5-methylcytosine): https://www.pnas.org/doi/10.1073/pnas.2123338119, “5-methylpseudouridine (m5c) RNA modification controls the innate immune response to virus infection by regulating type I interferons”, Jianrong Li, et al.; 23 August 2022. For m5U (5-methylpseudouridine): https://link.springer.com/article/10.1186/s12859-024-05978-1, “Deep-5mU: a deep learning-based approach for RNA 5-methyluridine modification prediction using optimized feature integration”, Nijad Ahmad, et al.; 19 November 2024. For m6A (N6-methyladenosine): https://www.abcam.com/en-us/technical-resources/pathways/m6a-functions-and-distribution. For s2U (2-thiouridine): https://pmc.ncbi.nlm.nih.gov/articles/PMC10870715/, “Unusual Base Pair between Two 2-Thiouridines and its implication for Nonenzymatic RNA copying”, Jack W. Szostak, et al.; 31 January 2024.

For the enzymatic digesters of RNA used in the Patent:

For RNaseIII (an inhibitor): https://www.medchemexpress.com/inhibitor-kit/rnase-iii.html. For RNaseV1 (cobra venom; cleaves dsRNA into fragments): https://pubmed.ncbi.nlm.nih.gov/2420800/, “On the recognition of helical RNA by cobra venom V1 nuclease”, H B Lowman, D E Draper; 25 April 1986. For “Dicer” (cleaves dsRNA): https://als.lbl.gov/first-detailed-look-at-rna-dicer/. For “Chipper” (enzyme digester), in commercial formulation: https://idealsuppliesllc.com/product/liquid-enzyme-and-digester/; in laboratory use formulation: https://www.biosynth.com/biologics/enzyes/enzymes-for-research.

Regarding the time frame “regulation” of the mechanism of the N1-methylpseudouridine formulation in the Patent (refer to the Patent exhibit, above): https://bioengineer.org/n1-methylpseudouridine-shapes-translation-dynamics/, 15 January 2026. The N1-methylpseudouridine formulation in the Weissman – Kariko Patent above was engineered to SLOW DOWN the movement of the mechanism in certain specific sequences. Please see: https://www.researchgate.net/publication/396853169_N1_Methylpseudouridine_Directly_Modulates_Translation_Dynamics, Rozman, B., et al.; 24 October 2025. **** This last is crucial in understanding that taking REPEATED injections of a modRNA COVID-19 bioweapon “vaccine” INCREASES THE POTENTIAL FOR CATASTROPHIC NEGATIVE CONSEQUENCES TO THE BRAIN, AS WELL AS TO THE BODY. This has to do not only with adults, the elderly, and persons with already-existing neurological and/or physical conditions: think of the numbers of CHILDREN who are being given this “vaccine” on the “recommendation” of a pediatrician, or of the AMA, or of the CDC.

Confirmation that this N1-methylpseudouridine invention by Dr. Weissman and Dr. Kariko — AMONG OTHER SIMILAR PATENTS by these inventors — is being used in both the Pfizer-BioNTech and in the Moderna modRNA COVID-19 bioweapon “vaccines”, is here: https://www.cas.org/resources/cas-insights/nobel-mrna, “Nobel worthy: mRNA vaccines beyond COVID”, 29 September 2023. Please see the screenshot from this article, below:

>>>>>>>>>>>>>>>>>>>>

There is one other consideration here: the fact that the FDA-issued Package Insert for COMIRNATY includes only the information that was supplied to that agency by Pfizer-BioNTech. The same applies to the FDA-issued Package Insert for SPIKEVAX and for mNEXSPIKE: the FDA relies only the information supplied to that agency by Moderna. The FDA has never, to Yours Truly’s belief, ordered an outside, independent analysis of the ingredients of any of these injectables to be performed.

There is WIDE leeway, per the Patent for US11060107B2, for multiple “versions” of the Weissman – Kariko N1-methylpseudouridine formulation that can be inserted into the lipid nanoparticles — which will then convey them throughout the body as seen in the Pfizer-BioNTech and in the Moderna COVID-19 modRNA bioweapon “vaccines.” There is leeway for “instant” OR for “slowed-down” mechanism results of the N1-methylpseudouridine formulation in these injectables. There is also leeway for OTHER Weissman – Kariko Patents for nucleoside-modified RNA inventions to be used in the above modRNA COVID-19 bioweapon “vaccines.”

>>>>>>>>>>>>>>>>>>>>

Questions:

What about the issue of Patent use royalty payments? Do Dr. Weissman and Dr. Kariko get a share of such royalty payments? Does the University of Pennsylvania (the current Assignee for the Patent) get royalty payments? What about that co-invention + co-ownership + sharing of use royalty payments agreement between NIH and Moderna regarding mRNA-1273 (SPIKEVAX) and (by inclusion language in the original agreement) mRNA-1283 (mNEXSPIKE)?

Finally, these additional questions: One: What about the persistence of COVID-19 modRNA bioweapon “vaccine” mRNA, plasmid DNA, and other “vaccine” ingredients in the body for years after “vaccination”? The Yale LISTEN study documented that this persistence can occur for 709 days post-“vaccination” (https://medicine.yale.edu/ycci/listen-study/. Hulscher, et al., have documented evidence of this persistence (and the adverse effects on health that they produce) that present at least 3.5 years post-final “vaccine” injection (https://www.thefocalpoints.com/p/breaking-vaccine-mrna-plasmid-dna, Nicolas Hulscher, 2 February 2026; note: this article contains an AI-generated image. Two: What about the proven phenomenon of “vaccine” shedding? Please see: www.midwesterndoctor.com/, and search “shedding.” What role does the N1-methylpseudouridine formulation from the above Patent, present in modRNA COVID-19 bioweapon “vaccines”, play in these areas — especially in light of the fact that the mechanism of this formulation in the body can either be instantaneous; or, can be “spread out” over time?

>>>>>>>>>>>>>>>>>>>>

ALL modRNA COVID-19 BIOWEAPON “VACCINES” MUST BE REMOVED FROM THE MARKET AND FROM USE IN THE UNITED STATES, IMMEDIATELY.

Peace, Good Energy, Respect: PAVACA1

(Intellectual Property Disclaimer and Notice: Except for the linked URLs and other items available on the Internet, the ideas and/or opinions in today’s offering are by PAVACA1 (M.E. Forbes, aka M.E.C. Forbes.) Credit must be given to PAVACA1 if ideas and/or opinions in today’s offering are used by other blog writers; by podcasters; or, in print or social media.)